Page 2 - Gland Pharma

Gland Pharma gets tentative nod from USFDA for generic Sugammadex injection

Drug firm Gland Pharma on Friday said it has received a tentative nod from the US health regulator for generic Sugammadex injection, which is indicated for reversing the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to patients during surgery. The company "has received tentative approval from the United States Food and Drug Administration (USFDA) for Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial...", Gland Pharma said in a regulatory filing. The product is the generic version of Merck Sharp & Dohme Corp's Bridion injection, 100 mg/mL, it added. The company will launch the product through its marketing partner on receipt of final approval, Gland Pharma said. According to IQVIA, the Sugammadex injection, 200 mg/2 mL and 500 mg/5 mL single-dose vial had US sales of about USD 615 million for 12 months ended April 2021, it added. Sugammadex injection is used to reverse the effects of the muscle relaxants ...

Gland Pharma shares rally over 9%; at 52-week high after Q1 earnings

Shares of Gland Pharma on Thursday jumped over 9 per cent after the company reported an 11.83 per cent increase in its consolidated net profit for the quarter ended June 30, 2021.

Gland Pharma shares rally nearly 8%; at 52-week high after Q1 earnings

Shares of Gland Pharma on Thursday jumped nearly 8 per cent after the company reported an 11.83 per cent increase in its consolidated net profit for the quarter ended June 30, 2021

Gland Pharma rallies 8% on strong revenue growth in June quarter

Gland Pharma said the growth in revenue was contributed from a mix of launch of new products and volume growth in existing products

Gland Pharma Q1 consolidated net profit up 12% to Rs 350.7 crore

Drug firm Gland Pharma on Wednesday reported an 11.83 percent increase in its consolidated net profit to Rs 350.7 crore for the quarter ended June 30, 2021, on account of robust sales in all markets.

Retail investors miss rally in Gland Pharma; stock up 118% over IPO price

At the time of its IPO, retail investors bid for only 24 per cent or 0.24 times of the shares set aside for them

After 100% gain since Nov, can the rally in Gland Pharma stock continue?

Gland's prospects remain strong, say analysts, as it has a robust pipeline of products with 50 pending Abbreviated New Drug Applications (ANDAs) and a healthy filing rate of 21 ANDAs in 9MFY21

Stocks to watch: Tata Motors, Airtel, Gland Pharma, HCL Tech, Orient Cement

Reliance Jio said it is constructing the largest international submarine cable system centred on India with global partners and submarine cable supplier Subcom to cater to increased data demand

Gland Pharma's Q4 consolidated net profit up 34% at Rs 260.4 crore

Drug firm Gland Pharma on Monday reported a 34 per cent rise in its consolidated net profit to Rs 260.4 crore for the fourth quarter ended March 2021, on account of robust sales

Gland Pharma hits new high; stock zooms 92% over issue price

The stock was trading higher for the fourth straight day, up 16 per cent during the period

Entrants' rally fizzles out: IPOs listed since Sept down 20% from peak

Shares of Antony Waste, Mrs Bectors Food, Chemcon Speciality and Burger King are down about 40 per cent each

Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement

Gland Pharma rises after bagging deal to supply Russia's Covid-19 vaccine

Analysts upbeat about company's revenues, but say it will have to bump up its capacity quickly to meet the Russian order

India emerges global manufacturing hub for Covid-19 vaccine Sputnik V

Gland Pharma to make 252 mn doses, Hetero 100 mn doses, Strides may also join the fray

Gland Pharma inks pact to supply 252 mn doses of Sputnik V Covid vaccine

The production is expected to commence from the third quarter of 2021 for estimated delivery starting from the fourth quarter of 2021

New launches, market share gains to sustain Gland Pharma's sales trajectory

Earnings are expected to grow over 25 per cent over the next two years

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

Street signs: Mrs Bector's GMP, Gland Pharma on FPI red-flag list and more

If grey market activity is to be believed, despite the high acquisition price, HNIs will make money.

Why retail, HNI investors may be regretting giving Gland Pharma IPO a miss

Gland Pharma, promoted by China's Fosun, has extended its gains, is up 40 per cent since its listing

Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%

Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE